Transcode therapeutics stock.

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules Read full article TransCode Therapeutics, Inc.BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it is withdrawing the underwritten public offering of its common stock. This reflects the Company’s belief …Nov 30, 2023 · BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock ... TransCode Therapeutics (NASDAQ:RNAZ) Co-Founder & CEO Michael Dudley joins Natalie Stoberman from the Proactive newsroom to share the latest progress from its lead RNA oncology candidate TTX MC 138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.First Quarter 2022 Financial Highlights. Cash and cash equivalents were $16.9 million at March 31, 2022, compared to $20.8 million at December 31, 2021. Research and development expense was $1.9 ...

Traders immediately bid up the RNAZ stock price this morning. It is truly a monumental day for TransCode Therapeutics (NASDAQ: RNAZ) stock. That’s because the company just disclosed the ...Dec 7, 2022 · TransCode Therapeutics (NASDAQ: RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won’t pursue a plan to sell 12 ... Get the latest Galera Therapeutics Inc (GRTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

25 thg 9, 2023 ... TransCode Therapeutics Inc (NASDAQ: RNAZ) shares are trading higher after the company announced results with its lead therapeutic candidate, ...

BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 5,000,000 shares of …TransCode’s Chief Technology Officer and co-founder, Dr. Zdravka Medarova, said, “TTX-MC138 is a first-in-class therapeutic candidate against cancer, not only because of its molecular ...TransCode Therapeutics (NASDAQ:RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...TransCode Therapeutics (NASDAQ: RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won’t pursue a plan to sell 12 ...26 thg 11, 2023 ... TransCode Therapeutics, Inc. | 1341 followers on LinkedIn. Delivering a cancer-free future. | TransCode's lofty goal is delivering a ...

We would like to show you a description here but the site won’t allow us.

Dec 1, 2023 · The Investor Relations website contains information about TransCode Therapeutics's business for stockholders, potential investors, and financial analysts.

Nov 24, 2023 · Stock analysis for TransCode Therapeutics Inc (RNAZ:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The consensus among analysts is that TransCode Therapeutics Inc (RNAZ) is a Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.TransCode Therapeutics (NASDAQ:RNAZ) Co-Founder & CEO Michael Dudley joins Natalie Stoberman from the Proactive newsroom to share the latest progress from its lead RNA oncology candidate TTX MC 138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.52-week price history of RNAZ Stock. A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. TransCode Therapeutics Inc’s current trading price is -99.06% away from its 52-week high, while its distance from the 52-week low is 46.59%.Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of TransCode Therapeutics, Inc. (NASDAQ:RNAZ), that sends ...

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules 3 GlobeNewswire (USA)In connection with the reverse stock split, the Company's CUSIP number will change to 89357L 204 as of 4:05 pm on Monday, May 22, 2023. About TransCode TherapeuticsBOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of ...TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules Read full article TransCode Therapeutics, Inc.AboutTransCodeTherapeutics. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The Company has created a platform of ...

About TransCode Therapeutics TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its iron oxide nanoparticle delivery platform, the Company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of …TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules Read full article TransCode Therapeutics, Inc.

Get the latest Transcode Therapeutics Inc (RNAZ) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, …PTC Therapeutics (NASDAQ: PTCT) stock is falling on Friday after the biopharmaceutical company released its earnings report for the third quarter of 2023. The bad news for PTCT stock starts with ...TransCode Therapeutics, Inc. 0.3599. +0.0338. +10.36%. BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed ...TransCode Therapeutics (NASDAQ:RNAZ) stock is taking a beating on Friday after the oncology company announced plans for a public share offering.TransCode Therapeutics Announces 1-for-20 Reverse Stock Split BOSTON, May 22, 2023 -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors approved a 1-for-20 reverse stock ...

0. On October 31, 2023, TransCode Therapeutics, a pioneering biotechnology firm, made a significant announcement. They revealed their decision to withdraw their underwritten public offering of common stock due to the prevailing market conditions, which they deemed unfavorable for conducting an offering that would truly benefit their stockholders.

Traders immediately bid up the RNAZ stock price this morning. It is truly a monumental day for TransCode Therapeutics (NASDAQ: RNAZ) stock. That’s because the company just disclosed the ...

BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2023, and recent business progress.25 thg 9, 2023 ... TransCode Therapeutics Inc (NASDAQ: RNAZ) shares are trading higher after the company announced results with its lead therapeutic candidate, ...Oncology firm TransCode Therapeutics prices 6.25M-share IPO at $4. Get the latest news and real-time alerts from TransCode Therapeutics, Inc. (RNAZ) stock at Seeking Alpha.Get Transcode Therapeutics Inc (RNAZ.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... TransCode Therapeutics, Inc. is a ...TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating …Stock Price Forecast The 1 analysts offering 12-month price forecasts for Transcode Therapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. Our Pipeline. TransCode Therapeutics has created a platform of therapeutic candidates with the objective of improving cancer patient outcomes. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has been shown to be responsible for the majority of all cancer deaths annually. More on TTX-MC138.Founded Date Jan 1, 2016. Founders R. Michael Dudley, Zdravka Medarova. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Transcode Therapeutics, Inc. Stock Symbol NASDAQ:RNAZ. Company Type For Profit. TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the …Oct 30, 2023 · TransCode Therapeutics, Inc. 0.3599. +0.0338. +10.36%. BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed ... Oncology firm TransCode Therapeutics prices 6.25M-share IPO at $4. Get the latest news and real-time alerts from TransCode Therapeutics, Inc. (RNAZ) stock at Seeking Alpha.

In connection with the reverse stock split, the Company's CUSIP number will change to 89357L 204 as of 4:05 pm on Monday, May 22, 2023. About TransCode TherapeuticsHow to Buy Stock in Transcode Therapeutics · Decide where to buy Transcode Therapeutics stock · Open your brokerage account · Deposit funds into your brokerage ...BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA ...TransCode Therapeutics (NASDAQ:RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of ...Instagram:https://instagram. non woke companies to work formessi world.cup jerseyis microsoft a good stock to buyhow much is a copper nickel worth Nov 17, 2023 · Transcode Therapeutics Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-5.570 per share for the current fiscal year. Transcode Therapeutics Inc does not currently pay a dividend. u roy stock6 month treasury rates 22 thg 5, 2023 ... (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, ...The Wall Street analyst predicted. that Transcode Therapeutics's share price could reach $3.00 by Oct 24, 2024. The average Transcode Therapeutics stock price prediction forecasts a potential upside of 1,150% from the current RNAZ share price of $0.24. best bank statement loan BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...TransCode Therapeutics (NASDAQ: RNAZ) stock is rocketing higher on Wednesday following positive study results. The big news here has to do with TTX-RIGA, which is the company’s immunotherapy ...